The Medicine Maker / Issues / 2020 / TSMM 0920
September 2020

September 2020

In September’s issue of The Small Molecule Manufacturer, we take a deep-dive into the history of Indian pharma and ask industry experts how the country is adapting to the changes caused by the COVID-19 pandemic. Meanwhile, in The Next Big Thing, we examine the pros and cons of continuous manufacturing and discover how the API manufacturing process can be de-risked. We also sit down with JoyL Silva, General Manager at Pfizer CentreOne.

Download PDF
Previous All Issues Next
Manufacture Small Molecules

A Year of Challenge and Opportunity

September 7, 2020

The COVID-19 pandemic has caused widespread disruption. And though pharma has had to overcome hurdles to manage the fallout, opportunities to show the industry’s commitment to its most important stakeholders – patients and employees – have emerged. As has the chance to implement new processes and technologies to maintain the continued development of the sector. Here, Deepak Sapra, Global Head of PSAI (Custom Pharma Services and Active Ingredients) at Dr. Reddy’s Laboratories, explains the company’s approach to dealing with the ongoing crisis.

1 min read

A Year of Challenge and Opportunity
Manufacture Formulation

The Crystal Maze

August 14, 2020

Unexpected hydrates of an API can cause a frustrating detour in the drug development pathway – the right analysis (and expertise) can help manufacturers find their way

0 min read

The Crystal Maze

Recommended

Recent Issues
May 2025
February 2025
December 2024
October 2024